Skin Cancer

Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma [Video]

Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma

Oncotarget published “Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma” which reported that prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution.

These authors characterized genomic and neoantigen changes between 23 paired primary and recurrent head and neck squamous cell carcinoma (HNSCC) tumors.

Within these tumors, they identified 6 genes which have predicted neoantigens in 4 or more patients.

Within HNSCC tumors examined in this Oncotarget research paper, there are neoantigens in shared genes by a subset of patients.

The presence of neoantigens in these shared genes may promote an anti-tumor immune response which controls tumor progression.

Dr. Brian A. Van Tine from The Washington University in St. Louis, The St. Louis Children’s Hospital as well as The Siteman Cancer Center said, “Head and neck cancer are a group of heterogeneous tumors with an estimated 644,000 new cases per year worldwide.”

The infiltration of immune cells, including T cells, into tumors is associated with improved outcomes and longer survival in HNSCC.

The infiltrating T cells release granules containing perforin and granzyme A and B which directly kill tumor cells or release other cytokines and chemokines that promote the anti-tumor immune response and alter the tumor microenvironment.

For example, infiltrating T cells release interferon gamma which increases expression of PD-L1 and CTLA-4, which may increase the efficacy of immune checkpoint therapy.

Multiple studies have characterized changes in mutation burden in HNSCC, when comparing primary and metastatic tumors, no studies have characterized the shifting neoantigen burden between primary and metastatic tumors within HNSCC.

In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC.

The Van Tine Research Team concluded in their Oncotarget Research Output that there is a shifting neoantigen burden as there are unique neoantigens in primary tumors and different unique neoantigens in the recurrent/metastatic tumors.

The patients which have these neoantigens in shared genes are patients which have higher total numbers of neoantigens.

What is clear is that patients with neoantigens in these shared genes also tend to have increased duration of survival with disease.

The increase in neoantigens and duration of survival with disease tends to be associated with increased CD3 CD8 density in the tumor and CD8A expression.

This suggests that patients with these shared neoantigens are associated with increased CD8 T cell infiltration and increased cytotoxic activity, which extends the patient’s life.

Sign up for free Altmetric alerts about this article


Full text –

Correspondence to – Brian A. Van Tine –

Keywords – head and neck squamous cell carcinoma, neoantigens, mutational evolution, tumor relapse, immune cell infiltration

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit or connect with:

SoundCloud –
Facebook –
Twitter –
LinkedIn –
Pinterest –
Reddit –

Oncotarget is published by Impact Journals, LLC please visit or connect with @ImpactJrnls

Media Contact

Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC

Watch/Read More
Skin Cancer

What does skin cancer look like? #shorts #cancer [Video]

Dr. Nick Campitelli demonstrates how to take a punch biopsy to test for skin cancer. #shorts #shortsvideo #cancer MAKE SURE TO SUBSCRIBE FOR ALL THE NEW EDUCATIONAL VIDEOS COMING!! 👉🏻For more information visit :​👉🏻Follow me on TikTok!!👉🏻Connect with me!!👉🏻Check out this video of how we remove an ingrown toenail!👉🏻Dr. Nick Campitelli Performs latest Minimally Invasive Bunion Surgery! Watch this video! Nick Campitelli is a podiatrist who specializes in foot and ankle surgery in the Akron and Cleveland Ohio area. He is the Residency Director of the Western Reserve Hospital / University Hospital Podiatric Medicine and Surgery Residency Program.*** All content found on the this YouTube video including: text, images, audio, or other formats were created for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you heard on this video. ***

Skin Cancer

"BAPoma" - BAP1-inactivated nevus/melanocytoma - mimic of nevoid melanoma (AIP France 2021-case 12) [Video]

This video is an excerpt from my one-day dermpath course in Paris, France, on October 8, 2021, for the Academie Internationale de Pathologie – Division Française (IAP French division). Full 5 hour video of the entire course is available for free here: Digital slide (H&E): Digital slide (BAP-1 immunostain): Video: Handout & figure images: A complete organized library of all my videos, digital slides, pics, & sample pathology reports is available here: (dermpath) & (bone/soft tissue sarcoma pathology). Please check out my Soft Tissue Pathology & Dermatopathology survival guide textbooks: ‬This video is geared towards medical students, pathology or dermatology residents, or practicing pathologists or dermatologists. Of course, this video is for educational purposes only and is not formal medical advice or consultation.Presented by Jerad M. Gardner, MD. Please subscribe to my channel to be notified of new pathology teaching videos.Follow me on:Snapchat: JMGardnerMDTwitter: @JMGardnerMDInstagram: @JMGardnerMDKiko: